In particular, DLBCL of the ABC-type or the recently specified MCD-type or cluster 5 harbor recurrent mutations in MYD88 and CD79B with dependency on constitutive BCR signaling (72, 88, 168, 169). This evidence concerns the gene MYD88 and diffuse large B-cell lymphoma.